Microwave ablation or plus monochemotherapy in elderly advanced non-small-cell lung cancer patients.
Microwave ablation or plus monochemotherapy in elderly advanced non-small-cell lung cancer patients. Minim Invasive Ther Allied Technol. 2019 Oct 17;:1-9 Authors: Wei Z, Li Q, Ye X, Yang X, Huang G, Li W, Wang J, Han X Abstract Objective: To evaluate the efficacy of microwave ablation (MWA) and MWA plus monochemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC). Material and methods: Patients with advanced NSCLC aged ≥70 years were retrospectively enrolled. MWA was performed at the primary tumor site. The end points included progression-free survival (PFS), response to MWA and overall survival (OS). Results: Fifty-four patients were enrolled; of these, 36 received monochemotherapy. Complete ablation was achieved in 42 patients (77.8%). The median PFS and OS were 4.9 months and 21.8 months, respectively. Univariate analyses showed that female patients had superior PFS (31.9 months [95% confidence interval (CI): 0.8-63.0]) vs. 5.0 months in male patients (95% CI: 2.0-8.0), p = .002). Female sex was associated with better OS (not reached vs. 10.8 months, 95% CI: 9.3-12.3, p = .003). Moreover, patients with primary tumor size
The objective of this paper is to synthesise current knowledge on ALK rearrangement and its impact on the management of advanced NSCLC. Several inhibitors of the tyrosine kinase of ALK (crizotinib, ceritinib, alectinib) have been approved as first line therapies in patients with advanced ALK positive NSCLC, which are associated with a better median progression-free survival than conventional chemotherapy. Unfortunately, the emergence of drug resistance leads to tumor progression. In patients with oligoprogressive disease if local ablative therapy can be effected, continuing with the same ALK tyrosine kinase inhibitor is on...
Publication date: Available online 15 November 2019Source: Biosensors and BioelectronicsAuthor(s): Liying Zhao, Huaixia Yang, Xiaoke Zheng, Jinge Li, Lihe Jian, Weisheng Feng, Jinming KongAbstractCytokeratin fragment antigen 21–1 (CYFRA 21–1) DNA is a crucial biomarker closely associated with non-small cell lung cancer. Here, we fabricated a novel electrochemical biosensor for ultrasensitive detection of CYFRA 21–1 DNA via polysaccharide and electrochemically mediated atom transfer radical polymerization (eATRP) dual signal amplification. Specifically, thiolated peptide nucleic acid (PNA) probes at 5&prim...
This study offers a great potential for ECL as an alternative safer radiosensitizer for increasing the RT efficiency against NSCLC. PMID: 31727206 [PubMed - as supplied by publisher]
Authors: Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW Abstract ROS1 gene fusions account for approximately 1-2% of all cases of non-small cell lung cancer (NSCLC). Similarly to anaplastic lymphoma kinase (ALK)-positive NSCLC, patients with ROS1+ NSCLC tend to have minimal smoking and be of the female sex. In most cases, adenocarcinoma is the dominant histology. The ROS1 gene has homology to ALK and this structural similarity formed the basis for utilizing ALK inhibitors for ROS1+ NSCLC. On the basis of impressive progression-free survival of 19.2 months from the PROFILE 1001 trial, crizotinib obt...
Conclusion: Leptin produced by CAF promotes proliferation and migration of NSCLC cells probably via PI3K/AKT and MAPK/ERK1/2 signaling pathways in a paracrine manner. PMID: 31119158 [PubMed - indexed for MEDLINE]
Conditions: Detection; Segmentation Intervention: Other: Automatic detection and segmentation of NSCLC tumors Sponsors: Maastricht University; Hospital Center Universitaire De Liege, Liege, Belgium.; University Hospital RWTH Aachen University, Aachen, Germany.; Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang street, Dalian 116001, China; University of California San Francisco, San Franc isco, California, CA. Active, not recruiting
Condition: Carcinoma, Non-Small-Cell Lung Interventions: Biological: Pembrolizumab; Biological: MK-5890 Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting
Condition: Carcinoma, Non-Small-Cell Lung Interventions: Biological: Pembrolizumab; Biological: MK-4830 Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting
Condition: Carcinoma, Non-Small-Cell Lung Interventions: Biological: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pemetrexed; Biological: MK-7684 Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting